J Wan1,2, D B Shin1, M N Syed1, K Abuabara3, A R Lemeshow4, J M Gelfand1,5. 1. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. 2. Section of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 3. Department of Dermatology, University of California San Francisco (UCSF), San Francisco, CA, USA. 4. Pfizer, Inc., New York, NY, USA. 5. Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Abstract
BACKGROUND: Staphylococcal and herpes simplex virus (HSV) infections are commonly recognized in atopic dermatitis (AD), but less is known about other types of infections. OBJECTIVES: To determine the risk of herpesvirus infections, serious infections and opportunistic infections in patients with AD. METHODS: We conducted a population-based cohort study using UK-based electronic medical records data. Patients with AD were each matched to up to five unaffected patients on age, practice and index date. AD severity was defined using treatments as a proxy. Outcomes were incident herpesvirus infections [cytomegalovirus (CMV), Epstein-Barr virus (EBV), HSV or varicella zoster virus (VZV)], serious infections and opportunistic infections. RESULTS: Among 409 431 children and 625 083 adults with AD matched to 1 809 029 children and 2 678 888 adults without AD, respectively, adjusted Cox regression models showed children and adults with AD had a 50-52% greater risk of HSV and 18-33% greater risk of VZV, with risk increasing in parallel with AD severity. CMV risk was elevated among children with AD [hazard ratio (HR) 2·50, 95% confidence interval (95% CI) 1·38-4·54] and adults with severe AD (HR 4·45, 95% CI 1·76-11·25). Patients with AD had a 26-40% increase in risk of serious infections, with severe AD carrying the greatest risk. Although rare, opportunistic infections were associated with all severities of AD in adults (overall HR 1·31, 95% CI 1·20-1·42), but were not associated with AD in children. All estimates remained consistent after excluding patients receiving immunosuppressive treatments for AD. CONCLUSIONS: AD is significantly associated with herpesvirus infections, serious infections and opportunistic infections in a 'dose-dependent' manner with increasing severity. AD may increase susceptibility to infections exclusive of immunosuppressive medications.
BACKGROUND: Staphylococcal and herpes simplex virus (HSV) infections are commonly recognized in atopic dermatitis (AD), but less is known about other types of infections. OBJECTIVES: To determine the risk of herpesvirus infections, serious infections and opportunistic infections in patients with AD. METHODS: We conducted a population-based cohort study using UK-based electronic medical records data. Patients with AD were each matched to up to five unaffected patients on age, practice and index date. AD severity was defined using treatments as a proxy. Outcomes were incident herpesvirus infections [cytomegalovirus (CMV), Epstein-Barr virus (EBV), HSV or varicella zoster virus (VZV)], serious infections and opportunistic infections. RESULTS: Among 409 431 children and 625 083 adults with AD matched to 1 809 029 children and 2 678 888 adults without AD, respectively, adjusted Cox regression models showed children and adults with AD had a 50-52% greater risk of HSV and 18-33% greater risk of VZV, with risk increasing in parallel with AD severity. CMV risk was elevated among children with AD [hazard ratio (HR) 2·50, 95% confidence interval (95% CI) 1·38-4·54] and adults with severe AD (HR 4·45, 95% CI 1·76-11·25). Patients with AD had a 26-40% increase in risk of serious infections, with severe AD carrying the greatest risk. Although rare, opportunistic infections were associated with all severities of AD in adults (overall HR 1·31, 95% CI 1·20-1·42), but were not associated with AD in children. All estimates remained consistent after excluding patients receiving immunosuppressive treatments for AD. CONCLUSIONS: AD is significantly associated with herpesvirus infections, serious infections and opportunistic infections in a 'dose-dependent' manner with increasing severity. AD may increase susceptibility to infections exclusive of immunosuppressive medications.
Authors: James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom Journal: Pharmacoepidemiol Drug Saf Date: 2007-04 Impact factor: 2.890
Authors: W-D Döcke; C Kiessling; M Worm; M Friedrich; A Pruss; M Weitz; S Prösch; F Kern; H-D Volk; W Sterry; K Asadullah Journal: Br J Dermatol Date: 2003-05 Impact factor: 9.302
Authors: Lavinia Paternoster; Marie Standl; Johannes Waage; Hansjörg Baurecht; Melanie Hotze; David P Strachan; John A Curtin; Klaus Bønnelykke; Chao Tian; Atsushi Takahashi; Jorge Esparza-Gordillo; Alexessander Couto Alves; Jacob P Thyssen; Herman T den Dekker; Manuel A Ferreira; Elisabeth Altmaier; Patrick Ma Sleiman; Feng Li Xiao; Juan R Gonzalez; Ingo Marenholz; Birgit Kalb; Maria Pino Yanes; Cheng-Jian Xu; Lisbeth Carstensen; Maria M Groen-Blokhuis; Cristina Venturini; Craig E Pennell; Sheila J Barton; Albert M Levin; Ivan Curjuric; Mariona Bustamante; Eskil Kreiner-Møller; Gabrielle A Lockett; Jonas Bacelis; Supinda Bunyavanich; Rachel A Myers; Anja Matanovic; Ashish Kumar; Joyce Y Tung; Tomomitsu Hirota; Michiaki Kubo; Wendy L McArdle; A J Henderson; John P Kemp; Jie Zheng; George Davey Smith; Franz Rüschendorf; Anja Bauerfeind; Min Ae Lee-Kirsch; Andreas Arnold; Georg Homuth; Carsten O Schmidt; Elisabeth Mangold; Sven Cichon; Thomas Keil; Elke Rodríguez; Annette Peters; Andre Franke; Wolfgang Lieb; Natalija Novak; Regina Fölster-Holst; Momoko Horikoshi; Juha Pekkanen; Sylvain Sebert; Lise L Husemoen; Niels Grarup; Johan C de Jongste; Fernando Rivadeneira; Albert Hofman; Vincent Wv Jaddoe; Suzanne Gma Pasmans; Niels J Elbert; André G Uitterlinden; Guy B Marks; Philip J Thompson; Melanie C Matheson; Colin F Robertson; Janina S Ried; Jin Li; Xian Bo Zuo; Xiao Dong Zheng; Xian Yong Yin; Liang Dan Sun; Maeve A McAleer; Grainne M O'Regan; Caoimhe Mr Fahy; Linda E Campbell; Milan Macek; Michael Kurek; Donglei Hu; Celeste Eng; Dirkje S Postma; Bjarke Feenstra; Frank Geller; Jouke Jan Hottenga; Christel M Middeldorp; Pirro Hysi; Veronique Bataille; Tim Spector; Carla Mt Tiesler; Elisabeth Thiering; Badri Pahukasahasram; James J Yang; Medea Imboden; Scott Huntsman; Natàlia Vilor-Tejedor; Caroline L Relton; Ronny Myhre; Wenche Nystad; Adnan Custovic; Scott T Weiss; Deborah A Meyers; Cilla Söderhäll; Erik Melén; Carole Ober; Benjamin A Raby; Angela Simpson; Bo Jacobsson; John W Holloway; Hans Bisgaard; Jordi Sunyer; Nicole M Probst Hensch; L Keoki Williams; Keith M Godfrey; Carol A Wang; Dorret I Boomsma; Mads Melbye; Gerard H Koppelman; Deborah Jarvis; Wh Irwin McLean; Alan D Irvine; Xue Jun Zhang; Hakon Hakonarson; Christian Gieger; Esteban G Burchard; Nicholas G Martin; Liesbeth Duijts; Allan Linneberg; Marjo-Riitta Jarvelin; Markus M Noethen; Susanne Lau; Norbert Hübner; Young-Ae Lee; Mayumi Tamari; David A Hinds; Daniel Glass; Sara J Brown; Joachim Heinrich; David M Evans; Stephan Weidinger Journal: Nat Genet Date: 2015-10-19 Impact factor: 38.330
Authors: Sinéad M Langan; Katrina Abuabara; Sarah E Henrickson; Ole Hoffstad; David J Margolis Journal: J Invest Dermatol Date: 2017-02-12 Impact factor: 8.551
Authors: Thomas Bieber; Eugen Feist; Alan D Irvine; Masayoshi Harigai; Ewa Haladyj; Susan Ball; Walter Deberdt; Maher Issa; Susanne Grond; Peter C Taylor Journal: Adv Ther Date: 2022-09-05 Impact factor: 4.070